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Abstract
Background: Human serum paraoxonase 1 (PON1) plays a major role in the metabolism of several
organophosphorus compounds. The enzyme is encoded by the polymorphic gene PON1, located on chromosome
7q21.3. Aiming to identify genetic variations related to the risk of developing brain tumors, we investigated the
putative association between common nonsynonymous PON1 polymorphisms and the risk of developing
astrocytoma and meningioma.
Methods: Seventy one consecutive patients with brain tumors (43 with astrocytoma grade II/III and 28 with
meningioma) with ages ranging 21 to 76 years, and 220 healthy controls subjects were analyzed for the frequency
of the nonsynonymous PON1 genotypes L55M rs854560 and Q192R rs662. All participants were adult Caucasian
individuals recruited in the central area of Spain.
Results: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms PON1 L55M and PON1
Q192R did not differ significantly between patients with astrocytoma and meningioma and controls. The minor
allele frequencies were as follows: PON1 55L, 0.398, 0.328 and 0.286 for patients with astrocytoma, meningioma and
control individuals, respectively; PON1 192R, 0.341, 0.362 and 0.302 for patients with astrocytoma, meningioma and
control individuals, respectively. Correction for age, gender, or education, made no difference in odds ratios and
the p values remained non-significant. Haplotype association analyses did not identify any significant association
with the risk of developing astrocytoma or meningioma.
Conclusions: Common nonsynonymous PON1 polymorphisms are not related with the risk of developing
astrocytoma and meningioma.
Background
Primary cancers of the brain and nervous system glob-
ally account for nearly 200,000 new cases per year, the
highest rates being observed in developed areas [1]. The
two most common histologic types of brain tumors in
adults are gliomas and meningiomas, and data suggest
that gliomas are more common in men, while meningio-
mas occur more often in women [2].
The etiology of brain tumors is still poorly under-
stood. Despite some studies suggested a possible
relationship between the risk for brain tumors and sev-
eral occupational and environmental exposures, includ-
ing farming [3-5] and pesticides and/or herbicides
[2,5-10], others failed to show this association [11-13]. A
recent multicenter case-control study examining inci-
dent glioma and meningioma risk associated with occu-
pational exposure to insecticides and herbicides showed
increased risk for meningioma in women who reported
ever using pesticides, with a trend of increasing risk
with increasing years of herbicide exposure [14]. Inter-
estingly, it has been reported that, in experimental mod-
els, organophosphorus insecticides and their oxons can
affect astroglial cell proliferation in cultures of astro-
cytoma-glioma cell lines or primary astrocytes [15,16].
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encoded by the polymorphic gene PON1 on chromo-
some 7q21.3, is an aryldialkylphosphatase, synthesized
mainly in the liver, that plays a major role in the meta-
bolism of several organophosphorus compounds, like
some insecticides, neurotoxins, and arylesters [17]. The
high variability in the activity of PON1 has been attribu-
ted to several polymorphisms within the gene, as well as
physiological and pathological states, dietary and lifestyle
factors and environmental chemicals. Two nonsynon-
ymous polymorphisms, a leucine to methionine substitu-
tion at position 55 (L55M, rs854560, c.220 T > A
according to the GenBank accession number NM
000446) and a glutamine to arginine substitution at
position 192 (Q192R, rs662, c.632 A > G according to
the GenBank accession number NM 000446), 8638 bp
apart, have been shown to influence PON1 activity
[18-20]. The M allele at position 55 causes a decrease in
protein stability [21] and the Q allele at position 192
has been associated with decreased metabolic activity
for some substrates [22,23]. In the serum, PON1 is asso-
ciated with high density lipoprotein (HDL), and plays an
important role in lipid metabolism as an antioxidant
molecule through several mechanisms [24-26]. In addi-
tion, PON1 is implicated in the elimination of carcino-
genic lipid-soluble radicals from lipid peroxidation [27].
Although astrocytoma and meningioma arise from
completely different types of cells, it cannot be ruled out
that some similar features may be involved in their etiol-
ogy. In some cases meningiomas can mimic astrocyto-
mas and vice-versa and some studies reported
concurrent occurrence of both tumors in the same
patient [28-35]. Moreover, genetic and non-genetic risk
factors have been associated with both types of tumors
[36,37]. To establish whether PON1 genotype and allelic
variants could be related to the risk of developing brain
astrocytoma and/or meningioma, we have compared the
prevalence of the PON1-L55M and PON1-Q 1 9 2 Rp o l y -
morphisms in the PON1 gene, in a group of 71 patients
with these brain tumors (43 with astrocytoma grade II/
III and 28 with meningioma), and 220 healty controls.
Methods
We studied 43 unrelated patients with brain astro-
cytoma grade II/III (26 men, 17 women; mean ± SD age
51.7 ± 17.4 years) and 28 with brain meningioma
(6 men, 22 women; mean ± SD age 62.1 ± 11.7 years).
The age ranges were 21-68 years for astrocytoma and
27-76 years for meningiomas. All consecutive patients
attending the participating hospitals (Hospital Universi-
tario “Doce de Octubre” (Madrid, Spain) and the Hospi-
tal Universitario Infanta Cristina (Badajoz, Spain))
between 1997 and 1999 that were diagnosed of astrocy-
toma grade II/III or brain meningioma were included in
the study, and none was excluded for any reason. Diag-
nosis was confirmed by histologic analysis in all patients.
These patients participated in a previous study by our
group [38]. The control group was composed of
220 healthy unrelated Caucasian Spanish individuals
(110 men and 110 women, most of them students or
staff from the University of Extremadura and from the
participating hospitals). The inclusion criteria were the
following: age over 18 and lack of all the exclusion
criteria. Exclusion criteria were history of neurological,
gastrointestinal, liver or renal disease. The control group
had a mean age of 44.5 ± 12.2 years.
All the participants were Caucasian Spanish indivi-
duals from the central area of Spain, and were included
in the study after giving written informed consent. The
protocol was approved by the Ethics Committees of the
Hospital Universitario “D o c ed eO c t u b r e ” (Madrid,
Spain) and the Hospital Universitario Infanta Cristina
(Badajoz, Spain).
A 10 mL venous blood sample was obtained from each
individual, collected in EDTA tubes and stored at -80°C
until analysis. Genomic DNA was isolated from leuko-
cytes by means of standard procedures. PON1 genotyping
was carried out by TaqMan assay designed to detect the
following SNPs: PON1 L55M, rs854560 and Q192R,
rs662 (C___2259750_20 and C___2548962_20, respec-
tively, Applied Biosciences Hispania, Alcobendas,
Madrid, Spain). The detection was carried out by qPCR
in a Eppendorf realplex thermocycler by using fluores-
cent probes. The amplification conditions were as
follows: After a denaturation time of 10 min at 96°C,
45 cycles of 92°C 15 sec 60°C 90 sec were carried out and
fluorescence was measured at the end of every cycle and
at endpoint. All samples were determined by triplicate
and genotypes were assigned both, by the gene identifica-
tion software (RealPlex 2.0, Eppendorf) and by analysis of
the reference cycle number for each fluorescence curve,
calculated by the use of CalQPlex algorithm (Eppendorf).
For every polymorphism tested, genomic DNA of twenty
individuals carrying no mutations, twenty heterozygotes
and twenty homozygotes were analyzed, by amplifica-
tion-restriction as described elsewhere [39-41] and in all
c a s e st h eg e n o t y p e sf u l l yc o r r e s p o n d e dw i t ht h o s e
detected with fluorescent probes.
The intergroup comparison values and the significance
of the gene-dose effect were calculated by using the chi-
square test or the Fisher’s exact test when appropriate.
Logistic regression was performed to verify that age,
gender or education did not modify the odds ratios.
Statistical analyses were performed using the SPSS 15.0
for Windows (SPSS Inc., Chicago, Illinois, USA). The
patient’s sample size was determined from allele fre-
quencies observed for healthy individuals with a genetic
model analyzing the frequency for carriers of the disease
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with the DeFinetti program (http://ihg2.helmholtz-
muenchen.de/cgi-bin/hw/hwa1.pl). Haplotype recon-
struction was carried out using the program PHASE
v2.1.1 with the default model for recombination rate
variation [42]. Seven independent runs with 1000 itera-
tions, 500 burn-in iterations and a thinning interval of
1 were performed as described elsewhere [43]. Associa-
tion tests were carried out with the software package
PLINK [44].
Results
No departures from HWE were observed. The p values
(Pearson) for HWE departures were as follows: PON1
L55M: cases, p = 0.620, controls, 0.142; PON1 Q192R:
cases, p = 0.962, controls, p = 0.544. The frequencies of
PON1 genotypes and PON1 alleles in patients with brain
tumors did not differ significantly from those of con-
trols, both considering astrocytoma plus meningioma
cases (Table 1), or astrocytoma and meningioma sepa-
rately (Table 2). Different genetic models were used to
test the genotypic associations. For overall patients the
results for association tests for the PON1 L55M poly-
morphism were as follows: Genotypic test, p = 0.879;
trend test, p = 0.691, dominant model, p = 0.847, reces-
sive model p = 0.612. Regarding the results for associa-
tion tests for the PON1 Q192R polymorphism in overall
patients were: Genotypic test, p = 0.542; trend test, p =
0.282, dominant model, p = 0.279, recessive model p =
0.567. For astrocytoma patients the results for associa-
tion tests for the PON1 L55M polymorphism were as
follows: Genotypic test, p = 0.989; trend test, p = 0.886,
dominant model, p = 0.884, recessive model p = 0.932.
Regarding the PON1 Q192R polymorphism, the associa-
tion test results were: Genotypic test, p = 0.727; trend
test, p = 0.465, dominant model, p = 0.424, recessive
model p = 0.778. For meningioma patients the results
for association tests for the PON1 L55M polymorphism
were as follows: Genotypic test, p = 0.605; trend test,
p = 0.386, dominant model, p = 0.605, recessive model
p = 0.323. Regarding the PON1 Q192R polymorphism,
the association test results were: Genotypic test,
p = 0.649; trend test, p = 0.353, dominant model,
p = 0.395, recessive model p = 0.524. We tested also the
frequencies for haplotypes and the P values for overall
patients, astrocytoma patients and meningioma patients,
respectively, were as follows: PON1 55L+192Q, 0.648,
0.945 and 0.384; PON1 55L+192R, 0.568, 0.721 and
0.557; PON1 55M+192Q, 0.560, 0.472 and 0.936; PON1
55M+192R, 0.291, 0.515 and 0.318.
Correction for age, gender, or education, made no
difference in odds ratios and the p values remained
non-significant.
Discussion
The brain is partially protected from chemical insults by
a physical barrier mainly formed by the cerebral micro-
vasculature, which prevents penetration of hydrophilic
molecules into the cerebral extracellular space [45].
However, several drugs and environmental pollutants,
including organophosphorus insecticides or other xeno-
biotics could reach the brain. This organ possesses an
enzymatic equipment able to metabolize xenobiotics,
like an entirely functional cytochrome P450 mono-oxy-
genase system in rodents and humans that would meta-
bolise xenobiotics resulting in the formation of reactive
and toxic metabolites in the neuronal cells [46]. Present
mainly in the liver and blood, PON1 should hypotheti-
cally act as a detoxifying enzyme at this level, causing
the hydrolysis of the acetylcholinesterase-inhibiting
Table 1 PON1 genotype and allelic variants of patients with brain tumor (BT) and healthy volunteers
BT PATIENTS (N = 73, 146 chromosomes) CONTROLS (N = 220, 440 chromosomes) OR (95% CI); P
GENOTYPES
PON1 55 Leu/Leu 11 (15.1) [6.9-23.3] 38 (17.3) [12.3-22.3] 0.85 (0.41-1.75); 0.662
1
PON1 55 Leu/Met 32 (43.8) [32.5-55.2] 94 (42.7) [36.2-49.3] –
PON1 55 Met/Met 30 (41.1) [29.8-52.4] 88 (40.0) [33.5-46.5] 1.05 (0.61-1.79); 0.869
2
PON1 192 Gln/Gln 31 (42.5) [31.1-53.8] 109 (49.5) [42.9-56.2] 0.75 (0.44-1.28); 0.295
1
PON1 192 Gln/Arg 33 (45.2) [33.8-56.6] 89 (40.5) [34.0-46.9] –
PON1 192 Arg/Arg 9 (12.3) [4.8-19.9] 22 (10.0) [6.0-14.0] 1.27 (0.57-2.85); 0.576
2
ALLELES
PON1 55 Leu 54 (37.0) [29.2-44.8] 170 (38.6) [34.1-43.2] 0.93 (0.63-1.37); 0.722
3
PON1 55 Met 92 (63.0) [55.2-70.8] 270 (61.4) [56.8-65.9] –
PON1 192 Gln 95 (65.1) [57.3-72.8] 307 (69.8) [65.5-74.1] –
PON1 192 Arg 51 (34.9) [27.2-42.7] 133 (30.2) [25.9-34.5] 1.24 (0.84-1.84); 0.289
3
The values in each cell represent: number (percentage) and [95% confidence intervals].
1The OR was calculated by using the dominant model.
2The OR was
calculated by using the recessive model.
3The OR was calculated by using the allelic model. Test for trend with the number of variant alleles: PON1 55 Leu/Met:
H = 0.0957 df = 1 p = 0.7570; PON1 192 Gln/Arg: H = 1.1416 df = 1 p = 0.2853.
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sphorus compounds [47,48], decreasing the possible
arrive of these compounds to the brain. Several evi-
dences point to pesticides as risk a factor for brain
tumors [49,50]. PON1 plays a prominent role among
the enzymes that prevent or mitigate damage caused by
reactive oxygen species. And hence it is conceivable that
changes in PON1 activity due to nonsynonymous poly-
morphisms may modulate the risk to develop brain
tumors.
Published evidences make it difficult to determine a
priori which PON1 isoform represents a risk factor for
the development of brain tumors. Although initial find-
ings point to the PON1-55M and PON1-192Q [21-23],
it should be remarked that there exists a differential
activity of PON1-192Q genotype towards different sub-
strates [51]. For that reason, besides genotypes, we ana-
lyzed all possible haplotypes and diplotype combinations
as putative risk factors, and we explored all genetic asso-
ciation models. Our findings did not indicate association
of the risk either with genotypes, allele frequencies, hap-
lotypes or diplotypes.
A few previous reports addressed the possible role of
PON1 polymorphisms in the risk for brain tumors:
Searles-Nielsen et al. observed no main effects or inter-
actions with insecticides for the Q192R and/or L55M
SNPs, but suggested that the functional C-108T poly-
morphism and insecticide exposures may be important
[52,53] Kafadar et al. [54] studied PON1-Q192R poly-
morphism and serum PON1 activity in 42 patients with
high grade gliomas, 42 patients with meningioma, and
50 controls. Although they found in both tumor groups
decreased PON1 activity when compared with controls,
PON1-Q192R genotype and allelic variants did not differ
between the study groups. Rajamaran et al. [55] studied
diverse gene polymorphisms related to oxidative
response, including the PON1-Q192R polymorphism, in
patients with glioma, meningioma, and acoustic neu-
roma. No association of the PON1-Q192R polymorph-
ism with the risk of developing any of these tumors was
identified.
I nt h ep r e s e n ts t u d yw ef o u n dn os i g n i f i c a n td i f f e r -
ences either in PON1-55 or PON1-192 allele frequencies
or genotype frequencies between patients with menin-
gioma or grade II/III astrocytoma, as compared with
healthy control subjects.
A limitation of this study is that control subjects are
younger than patients and that it cannot be ruled out
that some control individuals would eventually develop
brain tumors. Nevertheless, the possibility that some
healthy subject would eventually develop these tumors
in the lapse between the mean age of controls and the
mean age of cases is negligible given the prevalence of
these tumors in the studied population, and therefore
the differences in the mean age of patients and controls
reflects that the control group is not fully comparable to
Table 2 PON1 genotype and allelic variants of patients with different types of brain tumor
Astrocytoma (N = 44, 88
chromosomes)
OR (95% CI); P Meningioma (N = 29, 58
chromosomes)
OR (95% CI); P
GENOTYPES
PON1 55 Leu/Leu 8 (18.2) [6.8-29.6] 1.07 (0.47-2.43);
0.885
1
3 (10.3) [0-21.4] 0.55 (0.17-1.81);
0.345
1
PON1 55 Leu/Met 19 (43.2) [28.5-57.8] – 13 (44.8) [26.7-62.9] –
PON1 55 Met/
Met
17 (38.6) [24.2-53.0] 0.94 (0.49-1.82);
0.866
2
13 (44.8) [26.7-62.9] 1.22 (0.57-2.62);
0.619
2
PON1 192 Gln/
Gln
19 (43.2) [28.5-57.8] 0.77 (0.41-1.48);
0.442
1
12 (41.4) [23.5-59.3] 0.72 (0.33-1.56);
0.409
1
PON1 192 Gln/
Arg
20 (45.5) [30.7-60.2] – 13 (44.8) [26.7-62.9] –
PON1 192 Arg/
Arg
5 (11.4) [2.0-20.7] 1.15 (0.43-3.14);
0.786
2
4 (13.8) [1.2-26.3] 1.44 (0.48-4.34);
0.531
2
ALLELES
PON1 55 Leu 35 (39.8) [29.5-50.0] 1.05 (0.66-1.67);
0.842
3
19 (32.8) [20.7-44.8] 0.77 (0.44-1.38);
0.386
3
PON1 55 Met 53 (60.2) [50.0-70.5] – 39 (67.2) [55.2-79.3] –
PON1 192 Gln 58 (65.9) [56.0-75.8] – 37 (63.8) [51.4-76.2] –
PON1 192 Arg 30 (34.1) [24.2-44.0] 1.19 (0.74-1.94);
0.474
3
21 (36.2) [23.8-48.6] 1.31 (0.74-2.31);
0.355
3
The values in each cell represent: number (percentage) and [95% confidence intervals].
1The OR was calculated by using the dominant model.
2The OR was
calculated by using the recessive model.
3The OR was calculated by using the allelic model. Test for trend with the number of variant alleles: Astrocytoma PON1
55 Leu/Met: H = 0.0360 df = 1 p = 0.8496; PON1 192 Gln/Arg: H = 0.5537 df = 1 p = 0.4568. Meningioma PON1 55 Leu/Met: H = 0.5987 df = 1 p = 0.4391; PON1
192 Gln/Arg: H = 0.8057 df = 1 p = 0.3694.
Martínez et al. BMC Neurology 2010, 10:71
http://www.biomedcentral.com/1471-2377/10/71
Page 4 of 7cases, but it should not influence the findings obtained
in the present study. Regarding the geographical origin
of the patients and controls, no genetic differences are
expected because all participants were Spanish Cauca-
sians living in close areas and because in previous
genetic studies we have not detected any genetic differ-
ences between individuals from Extremadura and
Madrid [56-60]. Another limitation of this study is the
absence of data regarding exposure to chlorpyrifos or
diazinon. Nevertheless, it should be stated that a recent
study that identified interaction between exposure to
insecticide treatment and some polymorphisms of pesti-
cide metabolism genes failed to identify a significant
interaction of exposure with the nonsynonymous PON1
polymorphisms analyzed in the present study [53]. Addi-
tional limitations are the inability to analyze other func-
tional PON1 SNPs, such as the highly functional
C-108T SNP, and the lack of PON1 activity measure-
ments, although this does not invalidate the findings
indicating the lack of a major genetic association with
the SNPs analyzed in this study. In fact, clinical associa-
tion of PON1 polymorphisms, but not PON1 enzyme
activity, with ischemic stroke has been recently demon-
strated [61] and vice-versa, no association between adult
brain tumors and PON1 genotype, but positive associa-
tion with PON1 activity has been described [54]. In this
regard, Furlong et al. recommend both, genotype deter-
mination and measurement of serum enzyme activity
for evaluation of PON1’s role in risk of disease or expo-
sure [62].
Another limitation of this study is the sample size of
subgroups of patients according to the histological type
o ft u m o r .I nt h i ss t u d yw ec a n n o te x c l u d eaf a l s en e g a -
tive result due to the sample size. Nevertheless, the
study is sufficiently powered to rule out a major associa-
tion of PON1 polymorphisms. For patients with astrocy-
toma the study can rule out an association with OR
≥ 2.1, and for patients with meningioma the study can
rule out an association with OR ≥ 2.5. Sporadic disease-
genotype associations this strong are extremely rare,
particularly with cancer risk [63-65]. Even considering
this limitation, this study indicates the absence of a
major association of the nonsynonymous PON1 poly-
morphisms studied with brain tumors.
Conclusions
Common nonsynonymous PON1 polymorphisms are
not related with the risk of developing astrocytoma and
meningioma.
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